Mass spectrometry is an ever evolving technology that is equipped with a variety of tools for protein research. Some lipoprotein studies, especially those pertaining to HDL biology, have been exploiting the versatility of mass spectrometry to understand HDL function through its proteome. Despite the role of mass spectrometry in advancing research as a whole, however, the technology remains obscure to those without hands on experience, but still wishing to understand it. In this review, we walk the reader through the coevolution of common mass spectrometry workflows and HDL research, starting from the basic unbiased mass spectrometry methods used to profile the HDL proteome to the most recent targeted methods that have enabled an unprecedented view of HDL metabolism.
INTRODUCTION
Despite the importance of lipoproteins such as VLDL, LDL and HDL to human physiology and the ongoing pursuit to manage their levels in dyslipidemic patients, research is still needed to fully understand these complex particles. Lipoproteins vary in macromolecular content, protein, triglycerides, and cholesterol and lipids. The protein constituents of HDL in particular have been heavily dissected in recent years, primarily through liquid chromatography mass spectrometry (LC-MS), revealing several more proteins additional to the classical apolipoproteins, such as apoA-I, apoA-II, apoE and apoC-III, whose biological activities are diverse [1] but still encompass the role for HDL as antiatherogenic particle. Moreover, LC-MS technology has extended well beyond a tool for identification. Changes in apolipoprotein abundance can now be readily assessed using one or more of a number of strategies including label-free and label-based strategies [2
&&
,3]. Quantitative proteomics provides several innovative workflows that are poised to address many of the unknowns of apolipoprotein function and metabolism. In this review, we detail the most recent developments in quantitative proteomics and how we and others have applied them to investigate the complex nature of the HDL proteome.
In the last 10 years, several proteomics studies have reported between 18 and more than 170 HDL-associated proteins (Fig. 1a) . The discrepancy in protein number is because of one or more factors: each HDL isolation and separation strategy may introduce unique protein contaminants or deplete bone fide HDL proteins; protein fractionation and proteolysis methods vary in peptide recovery and yield; recent studies that have capitalized on improved ionization technology, speed, sensitivity and accuracy of mass spectrometers would have observed lower abundant proteins; and the criteria for reporting HDL proteins vary from study to study. The health status and lipid profile of the study individuals also impact the composition of the HDL proteome, biological variables that are often evaluated in HDL proteomics studies. Nonetheless, despite all of the sources of variability listed above, approximately 90 proteins have persisted, and are thought to comprise the consensus HDL proteome [4 & ]. We analyzed the consensus proteome using the Markov cluster algorithm provided by the String database (http://string-db.org/) that sorted HDL's proteins into two major functional networks, one pertaining to lipid metabolism, and the other grouping several biological processes including protein activation cascades, regulation of wound response and regulation of protease activities (Fig. 1b) . The diversity in both HDL's protein constituents and their associated biological processes has repositioned HDL research to extend beyond its canonical role in lipid metabolism [5] 
Data-dependent acquisition mass spectrometry
Unbiased proteome profiling is primarily done using 'bottom-up' proteomics, a method that identifies proteins based on their proteolytic forms, peptides. In contrast, 'top-down' proteomics is the analysis of intact proteins and is more suitable for studying protein isoforms or post-translational modifications. ApoA-I isoforms, for example, have been studied using top-down approaches [7, 8] . For numerous reasons including a significantly simpler mass spectrometric signal to interpret, bottom-up is the standard approach for routine proteomics. The majority of proteomics studies are done using data-dependent acquisition (DDA) and will be the focus of this review. The other acquisition method, data-independent acquisition, which is not as common as DDA, is reviewed elsewhere [9, 10] .
In a standard DDA run, the mass spectrometer surveys the incoming peptide precursor ion signals (MS1s) to select a user-defined number of peptides to be fragmented in the subsequent scans (MS2). The number of peptides fragmented per cycle varies from study to study, however, up to the 20 most abundant peptides are generally selected per cycle (2 s). The isolation window around the precursor's m/z (mass-to-charge) of the peptide is as narrow as possible (e.g. þ/-1 m/z) in order to increase specificity of the target peptide by decreasing the interference by other peptide signals (Fig. 1c) , but not too narrow as signal loss will occur. When the isolation window is optimal, the fragment ions are more likely to belong to the isolated precursor and thus the quality of peptide sequencing is improved (Fig. 1c) . We will return to the relevance of the isolation window size when we overview recent advancements in targeted platforms below.
Label-free proteomics provides insight into HDL heterogeneity
Quantitative proteomics is generally categorized as label-free or label-dependent. Label-free employs either spectral counting (the total number of peptide-spectrum matches per protein) or the area under the curve of the peptides' chromatographic peaks [2 && ], under the observation that the more abundant a protein is in the sample, the more likely its peptides are detected and sequenced (Fig. 1d ).
KEY POINTS
Global proteomics studies have demonstrated that the HDL proteome comprises between 90 and 100 proteins.
The HDL proteome is differentially distributed across the HDL size fractions giving rise to a heterogeneous population of HDL particles.
There is an increase in targeted mass spectrometrybased research to understand the regulation and metabolism of subsets of HDL proteins.
Although MRM technology is the more commonly employed targeted mass spectrometry method, PRM is likely to increase in its use for HDL protein studies.
PRM was instrumental for revealing the unique metabolic profiles of seven classical apolipoproteins across five HDL size fractions, underscoring the capability for this technology to address the many unknowns of HDL function and metabolism in basic and clinical research.
A majority of the quantitative HDL proteomics studies have relied on spectral counting (Fig. 1a) . Some of these studies have specifically addressed whether proteins are differentially localized across HDL size or density fractions [2 && ,4 & ,11,12]. For instance, spectral counting was used to evaluate the comigration of HDL proteins across various analytical separation methods under the assumption that proteins residing on the same particle are more likely to be identified together within subfractions of each method. Human plasma HDL was fractionated using one of three methods, size exclusion chromatography, anion exchange chromatography or isolectric focusing, followed by a calcium silicate hydrate-dependent enrichment of the phospholipid compartment from each fraction per method [11] . The proteins were found to be differentially localized across the fractions for all three methods. For example, 106 proteins were reported from the size exclusion experiment whose fractions 13-29 represented the largest to smallest HDL sizes, respectively. ApoA-I signal was detected in all 17 fractions but predominated in fractions 20-27. ApoA-II, the second most abundant HDL protein, was only detected in fractions 22-25. Some proteins, such as fibrinogen a and b chains (FGA and FGB), predominated in the larger sizes, whereas albumin and apoA-IV predominated in the smallest sizes [11] . We profiled the proteome of human plasma HDL that was isolated by immunopurfication of apoA-I followed by fractionation by nondenaturing polyacrylamide gel electrophoresis [2 && ]. Five size fractions, preb, a3, a2, a1 and a0 (Fig. 2a) [2 && ], were in-gel proteolyzed for parallel quantitative proteomics approaches including spectral counting. We limited the proteins to those supported by two or more peptides per donor (between 76 and 105 proteins across three donors), then filtered the list down to those in common to the three donors (58 proteins) . Figure 2b features a heat map from one donor's normalized spectral counts from 23 of the 58 HDL proteins, sorted from a0 to preb. ApoA-I signal was detected in all five fractions, but predominated in a2 and a3; apoA-II's distribution was similar to that of apoA-I; FGA and FGB predominated the larger sizes, a0 and a1; and apoA-IV and albumin the smaller size fractions, a3 and preb (Fig. 2b) . Similar to the gel filtration data above, we too observed that the HDL proteome was organized in subgroups of proteins whose peak abundances were for the most part distributed within one or two adjacent size fractions [2 && ]. These and other global proteomics studies have thus provided the groundwork for further exploration on the extent of HDL particle heterogeneity [1, 13] . The differences in distribution of the HDL proteins across, for instance, the size fractions, indicate that subsets of proteins are more likely to co-occupy any given HDL particle.
Stable isotope labeling of apolipoproteins for their accurate quantification
Label-free proteomics is practical to gain an overview of a protein's relative abundance across samples, but not for the relative abundances among different proteins. This restriction is a consequence of differences in ionization efficiency -the number of (peptide) ions generated to the number of molecules consumed at the ionizing source of the instrument [14] . A peptide's intensity is therefore also dependent on its ionization efficiency. To account for differing ionization efficiencies for accurate quantification, label-based approaches are needed. Stable isotope-labeled peptide or protein standards can be spiked into samples at known quantities [2 && ,3,15]. The ionization efficiency of the endogenous 'light' peptide and its labeled 'heavy' standard is the same, thus the endogenous peptide's abundance is known by its relative abundance to its standard using the area under the curve method (Fig. 3a) .
Peptide standards were used to quantify 17 apolipoproteins (one standard per protein) in Lp(a), VLDL, LDL and HDL, isolated from healthy individuals by density centrifugation followed by size exclusion chromatography [16] . The relative distributions of the apolipoproteins within and among the lipoproteins varied; for example, after apoA-I, apoA-II and apoC-II were the second and third most abundant proteins on HDL and after apoB, apoC-II and apoC-III on VLDL and interestingly, apoA-I and apoC-II on LDL [16] .
In parallel to the spectral counting analysis highlighted in Fig. 2b , we also used peptide standards in combination with an apoA-I ELISA to determine the pool sizes for seven apolipoproteins, apoA-I, apoA-II, apoA-IV, apoC-III, apoD, apoE and apoM, in each HDL size fraction [2 && ]. In a2 for instance, the apoA-I pool size average for the three donors was approximately 1800 mg, whereas apoA-II and apoE were approximately 400 and 200 mg, respectively, and apoD was the lowest at 10 mg. Other studies have used labeled standards to estimate the apolipoprotein molecule number [16] or to monitor the relative abundances of HDL proteins from clinical samples, such as those from individuals with or without lupus; a study that identified a loss in PON3 in lupus individuals with a carotid artery plaque phenotype [17] .
Despite their value for accurate quantification, peptide standards are costly, approximately $500 per peptide. Stable isotope protein standards can also be synthesized at a lower cost, provided that the time and means to clone the gene of interest into the expression system is available [15] . As a consequence of the increased cost of label-based proteomics, standards are often used for only a subset of proteins using as few as one or as many as all observable peptides (if a protein standard is used) for labeling. Stable isotopes have also been used to create peptide tags in order to pool peptides derived from separate samples for a single mass spectrometric acquisition. These are generally referred to as tandem mass tagging approaches, as quantification information is contained in the tandem mass spectrometry scan (MS2). More information on tandem mass tagging and its application to HDL proteome research is provided elsewhere and in more detail [2 && ,18,19]. [20] . MRM is best performed on a quadrupole instrument that is specialized for isolating, one at a time, a predefined list of peptides for subsequent fragmentation, followed by isolation of a single fragment ion (transition) for detection (Fig. 3b, top panel) . MRM uses narrow isolation windows (1 Da) in order to reduce interference by background peptides, and is repeated for as many transitions the experimenter wishes to monitor. The more transitions monitored, the more confident the peptide identification. At least, three transitions are usually monitored per experiment with 50-100 transitions per second.
TARGETED PROTEOMICS APPLIED TO HDL BIOLOGY
In order to perform MRM, the target peptide's features, collectively referred to as a peptide library, must be known: the precursor and fragment ion m/z values, and the elution time from the chromatographic gradient. These features would have been established in previous DDA studies. Stable isotope labeled peptide standards are often implemented in targeted methods (Fig. 3b, bottom panel) because as standards, their transitions should be detected at the same elution time as the endogenous counterpart and they can be used for absolute quantification. However, monitoring the light and heavy peptides requires two independent scans. An alternative to MRM that has emerged in recent years is parallel reaction monitoring (PRM). Unlike MRM that is performed on a triple quadrupole instrument that scans at unit resolution (1Da), PRM is performed on the high-resolution/accurate mass quadrupole Orbitrap (Thermo Scientific) instrument (highresolution-multiple reaction monitoring for quadrupole time-of-flight instruments) that scans up to a resolution of 240 K (at 200 m/z) [20,21,22 && ]. A major advantage of PRM over MRM is that it is permissible to larger isolation windows as its high-resolution/ accurate mass scans can differentiate target ions from background ions (Fig. 3b) . As a consequence, all transitions are scanned simultaneously, permitting confident peptide identification in a single scan. In addition, the endogenous and standard peptides can be coisolated and relative quantification done at the same time (Fig. 3b) . In addition, high-resolution/accurate mass scans are about 10-times slower than those of MRM, thus fewer peptides are monitored per second. Nonetheless, as we will demonstrate below, the trade-off of high-resolution/accurate mass for speed makes PRM an increasingly attractive alternative to MRM for future targeted-based research [17,23- Monitoring HDL proteins using multiple reaction monitoring and parallel reaction monitoring
In the last 4 years, there has been a steady growth in the use of MRM to study HDL proteins (Fig. 3c) , however, PRM made its debut in lipoproteinrelated research in 2015 when it was demonstrated as an alternative to MRM for targeted HDL protein studies [46 & ], and to monitor circulating PCSK9 in rabbits fed a dual cholesteryl ester transfer proteinproprotein convertase subtilisin/kexin type 9 (CETP-PCSK9) small molecule inhibitor [44] . The studies in Fig. 3c have been used to monitor plasma levels of HDL proteins either related to their HDL biology directly, (i.e. [2 && ,55 & ] or to studies that identified HDL proteins in biomarker or target-discovery studies (i.e. [58, 60] ). Figure 3d is a tree map that scales the 35 monitored HDL proteins according to the number of times they were featured in the studies in Fig. 3c . ApoA-I and apoE were the most frequently monitored using MRM or PRM (Fig. 3d) .
Very recently, both MRM and PRM were used to determine the differences in the baseline proteome (before treatment) of HDL isolated from diabetic patients who either developed or were resistant to fenofibrate/rosiglitazone-induced hypoalphalipoproteinemia [55 & ]. A [15N]-labeled apoA-I protein standard was spiked into HDL samples for subsequent proteolysis and targeted mass spectrometry analysis. Its peptides served as a collective global standard for 37 other HDL protein peptides, a strategy that accounts for sample-to-sample variability without the cost of synthesizing standards for all proteins of interest. ApoA-I light and heavy peptides were measured by PRM in a manner similar to MRM, alternating between the light and heavy apoA-I target peptides in independent scans (Fig. 3b) . Two peptides for the 37 other HDL proteins were also monitored, and their signals normalized to the apoA-I standard peptides. As a consequence, PON1, apoC-I, apoC-II and apoH were found to be increased in the hypoalphalipoproteinemia individuals [ . Typically, individuals are administered a stable isotope-labeled amino acid (tracer), usually trideuterated-leucine (D3-Leu), which is taken up by organs such as the liver, and then incorporated into newly synthesized proteins such as apoA-I. The rate of appearance or disappearance of the tracer in circulating proteins provides information about their metabolism, and HDL itself by monitoring apoA-I metabolism [65, 66] . Gas chromatographymass spectrometry is the most common analytical method to monitor tracer enrichment by detecting the D0-Leu and D3-Leu pools; however, the MRM peptide-based detection method has been increasing in clinical use since it was introduced in 2006 [62] (Fig. 4a) . In the last few years, the metabolism of proteins such as apo(a), apoB, PCSK9 and CETP isolated from plasma or VLDL/LDL [27, 34, 54 && ,
63,64
&& ], or a subset of the classical apolipoproteins from HDL [52] have been studied in humans using MRM on the triple quadrupole platform (Fig. 4a) .
However, at unit resolution, MRM cannot reliably measure tracer enrichment in slowly turning-over proteins such as most of those in HDL. Thus, the scope of in-vivo metabolism studies is limited to proteins that are rapidly metabolized (apoB and apoE) or highly abundant (apoA-I and apoB). On the contrary, as we recently demonstrated, PRM's ability to coisolate and fragment multiple peptides (i.e. D0-Leu and D3-Leu peptides) (Fig. 3b) , and perform high-resolution/accurate mass scans permits the detection of tracer enrichment as low as 0.2% [2 && ]. Figure 4b shows an example of apoA-I fragment ion trace peak (D0-Leu) and the m/z range that contains tracer peak (D3-Leu). The inset zooms into the tracer range wherein the absence (0 h) and presence (2 and 6 h) of the tracer, and its differentiation from numerous background peaks, is evident. The difference in mass between the tracer and the closest background peak is only 11 mDa. Using MRM, on the other hand, the tracer and background peaks would have emerged as a single peak, resulting in inaccurate enrichment calculation. Figure 4c displays three prototypical enrichment profiles for apoA-I, apoA-II and apoE in a3 HDL. The panel highlights the remarkable contrast between the slowly turning over apoA-I and apoA-II, and the rapidly turning over apoE. Keeping in mind that all three proteins were isolated from the same HDL size fraction, these findings underscore that research aiming to understand the extent of HDL particle heterogeneity will also have to consider the significance of the varying metabolism profiles.
In order to expedite the use of PRM technology for future in vivo metabolism studies, we built a custom software especially designed to automate the detection and quantification of very low tracer peaks with high confidence [67] . By doing so, enrichment curve data for multiple HDL apolipoprotein were available within hours, instead of the days required when using traditional quantification methods [67] . Moreover, we monitored for the first time, the turnover of LCAT, in alpha2 and alpha3, and apoA-I in a size fraction smaller than that of prebeta [67] , further providing the lipoprotein field a unique vantage point of what these metabolic profiles indicate about HDL biology.
In summary, PRM is a very powerful method to detect low abundant peptide signals with confidence. Although we highlight its ability to detect low tracer incorporation, other applications include monitoring the oxidized form(s) of dysfunctional apoA-I in plasma and atheroma, which are currently dependent on antibody-based technologies [68] .
CONCLUSION
The overall finding from a number of global proteomics studies indicates that the constituents of the HDL proteome (90 proteins) have likely all been identified. A subset of these studies have also revealed that the proteins are differentially localized across the HDL sizes supporting the notion that HDL comprises a heterogeneous population of particles, in part defined by protein content. In order to better understand the molecular interactions among all classes of lipoprotein particles, targeted mass spectrometry methods such as MRM and PRM, in combination with stable isotope protein and peptide standards, are being used to quantify the relative proportions of their shared apolipoproteins. Moreover, because of the increased accuracy and sensitivity of PRM over MRM for tracer detection, PRM or other high-resolution/accurate mass-based technologies are likely to be more prominent in future in-vivo metabolism studies in a clinical environment. Future or existing lipid management trials can now monitor the metabolism of HDL apoA-I subfractions and additional apolipoproteins in response to these therapies; potentially revealing unique and overlapping mechanisms of each therapy on HDL (and other lipoproteins') metabolism. Moreover, a similar approach can be taken using animal models for drugs currently in development, with the additional benefit of access to all compartments (lipoproteins and organs) providing a more comprehensive metabolism picture.
